Basel is artificial intelligence hub
The canton of Basel-Stadt is one of the three largest Swiss technology clusters for advanced digitalization technologies, as the new Digitalization Atlas has revealed. It is especially strong in artificial intelligence, with Roche, in particular, filing many patents in this area.
Digitalization Atlas of Switzerland for the technology Artificial Intelligence (Image: EconSight)
The economic research and consulting company EconSight has published its latest Digitalization Atlas. In this, it examines the patent activities of companies in advanced digitalization technologies across the various regions of Switzerland, with the aim of highlighting where local technology clusters can be found.
According to the results, the canton of Basel-Stadt is one of the three largest clusters for advanced digitalization technologies in Switzerland. With these technologies, EconSight means artificial intelligence, encryption, big data, cloud computing and virtual reality. In total, companies and research facilities in the canton of Basel-Stadt have filed 202 patents in these areas.
According to the Digitalization Atlas, the technological focus of Basel-Stadt is artificial intelligence, with 75 percent of advanced digitalization patents within this field. This trend is above all driven by the Basel-based pharma giant Roche. In Switzerland, Roche holds the highest number of patents in artificial intelligence (115 patents). Roche is followed by Zurich technology company ABB (108 patents) and, by quite some margin, Google’s parent company Alphabet (40 patents).
Roche remains the clear leader even when all five technology categories are taken into account. With 149 patents, the Group ranks third behind the Western Swiss company Kudelski (213 patents) and ABB (196 patents).
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More